Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.
|ClinicalTrials.gov Identifier: NCT00423748|
Recruitment Status : Completed
First Posted : January 18, 2007
Last Update Posted : April 16, 2009
Information provided by:
A phase 3, randomized, double-blind, placebo-controlled study to assess safety and efficacy of ambrisentan in subjects with pulmonary arterial hypertension.
|Condition or disease||Intervention/treatment||Phase|
|Pulmonary Arterial Hypertension||Drug: ambrisentan||Phase 3|
Subjects in these randomized studies will receive one of two doses of ambrisentan or placebo. Inclusion is not based on a specified WHO functional classification. Rather, subjects with WHO Class I-IV symptoms are eligible if their 6-minute walk distance is 150-450 meters and they meet the study-specified hemodynamic criteria. Subjects with anorexigen or HIV infection related PAH are eligible but subjects with congenital heart disease and pediatric subjects are excluded. The study requires a historical cardiac catheterization and other diagnostic procedures.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||186 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Ambrisentan in PAH - A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects With Pulmonary Arterial Hypertension|
|Study Start Date :||December 2003|
|Estimated Study Completion Date :||February 2006|
Primary Outcome Measures :
- Change from baseline in the six-minute walk distance evaluated after 12 weeks of therapy compared to placebo.
Secondary Outcome Measures :
- Change from baseline measured after 12 weeks of treatment compared to placebo in the Borg Dyspnea Index; WHO Functional Classification; and the SF-36 Health Survey.
- Clinical worsening of PAH.
- Assessment of the safety and tolerability of the study drug.
No Contacts or Locations Provided